Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition

Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition is organized by Medtelligence.

Released: 04/14/2022
Valid until: 04/14/2023

Description:
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level. 

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Assess the need for disease-specific medical therapies for the management of hypertrophic cardiomyopathy (HCM)
• Evaluate the MOA and most recent efficacy and safety data for cardiac myosin inhibition in the treatment of HCM

Additional details will be posted as soon as information is available.